Pretreatment plasma renin activity levels correlate with the blood pressure response to telmisartan in essential hypertension.
BACKGROUND
Although the therapeutic response to angiotensin II receptor blockers (ARBs) is assumed impaired in patients with low-renin hypertension, data are scarce about the association between levels of plasma renin activity (PRA) before treatment and response of ambulatory blood pressure (ABP) to ARBs in essential hypertension.


METHODS
We prospectively studied 11 untreated Japanese patients with essential hypertension (3 women and 8 men, mean age: 50 +/- 9 (mean +/- SD) years). After a 4-week drug-free period, telmisartan 20-40 mg was administered orally once daily for 8 weeks. PRA levels were measured before treatment. The first ABP measurement was performed at the end of the drug-free period and the second measurement at the end of the treatment period with telmisartan.


RESULTS
Telmisartan significantly decreased the 24-h ABP by 12 +/- 11 mm Hg systolic (P < 0.01) and 9 +/- 8 mm Hg diastolic (P < 0.01). Reductions in the 24-h systolic and diastolic ABPs were significantly greater in five patients with higher renin levels (> or =0.65 ng/ml/h) than in six patients with lower renin levels (<0.65 ng/ml/h) by 18 mm Hg systolic (P < 0.001) and 11 mm Hg diastolic (P < 0.05). Changes in the 24-h systolic and diastolic ABPs significantly correlated with log PRA before treatment.


CONCLUSIONS
The ABP lowering effects of telmisartan were dependent on PRA levels before treatment in patients with essential hypertension. Measurement of PRA levels before treatment is thought to be useful for prediction of the ABP lowering effects of telmisartan.
Minami
Junichi
J
Department of Hypertension and Cardiorenal Medicine, Dokkyo University School of Medicine, Mibu, Tochigi, Japan. j-minami@dokkyomed.ac.jp
Ishimitsu
Toshihiko
T
Matsuoka
Hiroaki
H
D000284:Administration, Oral; D000328:Adult; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage / Q000627:therapeutic use*; D044466:Asian People; D001562:Benzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D001565:Benzoates / Q000008:administration & dosage / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects*; D018660:Blood Pressure Monitoring, Ambulatory; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D007564:Japan; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D011446:Prospective Studies; D012083:Renin / Q000097:blood*; D000077333:Telmisartan; D016896:Treatment Outcome
D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001565:Benzoates; D015415:Biomarkers; D012083:Renin; D000077333:Telmisartan